000 02324cam a2200337 a 4500
003 EG-GiCUC
005 20250223031519.0
008 160606s2016 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.08.08.Ph.D.2016.Wa.L
100 0 _aWalaa Ahmed Mohamed Eldakroury
245 1 0 _aLornoxicam colon targeting solid dosage form, design, formulation and evaluation /
_cWalaa Ahmed Mohamed Eldakroury ; Supervised Mahmoud M. Ghorab , Howida Kamal Ibrahim
246 1 5 _a إستھداف عقار اللورنوكسيكام للقولون: صياغة و تقييم
260 _aCairo :
_bWalaa Ahmed Mohamed Eldakroury ,
_c2016
300 _a185 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520 _aNon steroidal anti-inflammatory drugs (NSAIDs) got high importance as they inhibit the progression of cancer especially colon cancer. They can reduce the size of current tumor; increase the efficiency of anticancer agents and radiotherapy. However, long-term uses of non-selective NSAIDs can lead to gastrointestinal toxicity from sustained inhibition COX. Lornoxicam is a non steroidal anti-inflammatory drug of oxicam class and it has the same side effects of this group when taken orally and has a relatively short plasma half-life (3 to 4 h) which makes it a good candidate for colon targeting. It could avoid the systemic side effects, enhance its low oral bioavailability due to hepatic first pass metabolism and delay drug release to target the colon and lower the extent of colorectal carcinomas. The present study was carried out to develop oral colon targeted drug delivery systems for Lornoxicam utilizing many strategies as pH sensitive, pressure dependent, microbially triggered and time dependent enteric coating of granules, tablet and beads
530 _aIssued also as CD
653 4 _aLornoxicam colon
653 4 _aSolid dosage
653 4 _aTargeting
700 0 _aHowida Kamal Ibrahim ,
_eSupervisor
700 0 _aMahmoud Mohamed Ghorab ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSoheir
_eCataloger
942 _2ddc
_cTH
999 _c56810
_d56810